Chimeric antigen receptor (CAR) comprising a CD19-binding domain
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
1. A chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a VH domain having the sequence shown as SEQ ID NO: 24, and a VL domain having the sequence shown as SEQ ID NO: 26 or SEQ ID NO: 40.
2. A CAR according to claim 1 , wherein the CD19 binding domain comprises the sequence shown as SEQ ID NO: 22 or SEQ ID NO: 39.
3. A cell comprising a CAR according to claim 1 .
4. A nucleic acid sequence encoding a CAR according to claim 1 .
5. A vector which comprises a nucleic acid sequence according to claim 4 .
6. A method for making a cell according to claim 3 , which comprises the step of introducing into a cell:
a nucleic acid sequence encoding a CAR comprising a CD19-binding domain which comprises a VH domain having the sequence shown as SEQ ID NO: 24, and a VL domain having the sequence shown as SEQ ID NO: 26 or SEQ ID NO: 40, or
a vector comprising the nucleic acid sequence encoding the CAR.
7. A pharmaceutical composition comprising a plurality of cells according to claim 3 .